SEARCH

SEARCH BY CITATION

References

  • 1
    Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004; 18: 485492.
  • 2
    Cattaneo D, Gaspari F, Ferrari S et al. Pharmacokinetics helps optimizing mycophenolate mofetil dosing in kidney transplant recipients. Clin Transplant 2001; 15: 402409.
  • 3
    Hale MD, Nicholls AJ, Bullingham RE et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672683.
  • 4
    Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant Proc 1996; 28: 925929.
  • 5
    Van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral MMF for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261266.
  • 6
    Yamani MH, Starling RC, Goormastic M et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000; 69: 23262330.
  • 7
    Van Besouw NM, Van Der Mast BJ, Smak Gregoor PJ et al. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant 1999; 14: 27102713.
  • 8
    Mourad M, Malaise J, Chaib Eddor D et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47: 8894.
  • 9
    Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51: 278298.
  • 10
    Bullingham RE, Nicholls AJ, Kamm BR. Clinical Pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429455.
  • 11
    Shipkova M, Strassburg CP, Braun F et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 2001; 132: 10271034.
  • 12
    Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 10601067.
  • 13
    Zucker K, Rosen A, Tsaroucha A et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5: 225232.
  • 14
    Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000; 14: 100104.
  • 15
    Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acd glucuronidation. Ther Drug Monit 1999; 21: 3543.
  • 16
    Smak Gregoor PJ, Van Gelder T, Hesse CJ, Van Der Mast BJ, Van Besouw NM, Weimar W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: A cross-sectional study. Nephrol Dial Transplant 1999; 14: 706708.
  • 17
    Van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119128.
  • 18
    Hesselink DA, Van Hest RM, Mathot RAA et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005; 5: 987994.
  • 19
    Napoli KL, Taylor PJ. From beach to bedside: History of the development of sirolimus. Ther Drug Monit 2001; 23: 559586.
  • 20
    Johnson RW. Sirolimus (Rapamune) in renal transplantation. Curr Opin Nephrol Hypertens 2002; 11: 603607.
  • 21
    Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 12521260.
  • 22
    Renders L, Steinbach R, Valerius T, Schcklmann HO, Kunzendorf U. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res 2004; 27: 181185.
  • 23
    Gaspari F, Perico N, Ruggenenti P et al. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 1995; 6: 257263.
  • 24
    Cattaneo D, Perico N, Gaspari F. Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 2002; 774: 187194.
  • 25
    Perico N, Ruggenenti P, Gaspari F et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992; 54: 5660.
  • 26
    Schutz E, Shipkova M, Armostrong VW et al. Therapeutic drug monitoring of mycophenolic acid: Comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998; 30: 11851187.
  • 27
    Weber LT, Shipkova M, Armstrong VW et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002; 48: 517525.
  • 28
    Shaw LM, Sollinger HW, Halloran P et al. Mycophenolate mofetil: A report of the consensus panel. Ther Drug Monit 1995; 17: 690699.
  • 29
    Shaw LM, Nicholls A, Hale M et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 1998; 31: 317322.
  • 30
    Pawinski T, Hale M, Koreka M, Fitzsimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48: 14971504.
  • 31
    Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004; 75: 434437.
  • 32
    Kuypers DR, Vanrenterghem Y, Squifflet JP et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003; 25: 609622.
  • 33
    Mourad M, Malaise J, Chaib Eddour D et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001; 47: 12411248.